Document is current

Article History

Accepted: 1 May 2022

First Online: 25 May 2022

Declarations

:

: This study was approved by the Institutional Review Board of the Japanese Foundation for Cancer Research (Tokyo, Japan, registry number 2019–1034). The protocol was described on the hospital website, and subjects were provided the opportunity to opt out; therefore, no additional consent was required from patients. All methods were performed in accordance with the Declaration of Helsinki.

: Dr. Takahashi has received honoraria from Taiho, Chugai, Asahikasei, Bayer, Japan Blood Products Organization, Medicon, Termo, Sanofi, Merckbiopharma, Nippon-kayaku, Takeda, Ono, and Yakult and research grant from Merckbiopharma; Ono. Dr. Shinozaki has received honoraria from Taiho, Chugai, Merckbiopharma, Takeda, Sanofi, Eli Lilly, and Daiichi-Sankyo; and Ono. Pr. Ishioka has received honoraria from Chugai, Taiho, Ono, Merckbiopharma, Novartis, Asahi Kasei, Sanofi, Nippon-Kayaku, Daiichi Sankyo, Takeda, Bayer, Eisai, Eli Lilly, Teijin, Hitachi, Bristol-Myers Squibb, Konica Minolta, Pfizer, and Yakult as well as research grant from Hitachi, Riken Genesis, Yakult, Taiho, Ono, Asahi Kasei, Sanofi, Takeda, Eisai, Chugai, Kyowa Kirin, Tsumura, Eli Lilly, Otsuka, Shionogi, Novartis, Daiichi Sankyo, and Nippon-Kayaku. All other authors declared no competing interests.